BioCentury
ARTICLE | Emerging Company Profile

InflaRX: Safety in Sepsis

May 4, 2009 7:00 AM UTC

Xigris drotrecogin alfa is the only drug approved to treat sepsis, but a narrow label and bleeding risks have limited its use to severely septic patients at high risk of death. InflaRx GmbH believes its antibodies against undisclosed activation products of the complement system will be safer and more broadly applicable.

"We know that these activation products are heavily involved in the initial strong response, so they are directly involved in the organ damage, but also in the long run in the development of paralysis of the immune system," co-founder and CEO Niels Riedemann told BioCentury...